Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/120651
Full metadata record
DC FieldValueLanguage
dc.contributor.authorZurita, A. J.-
dc.contributor.authorDiestra, J. E.-
dc.contributor.authorCondom i Mundó, Enric-
dc.contributor.authorGarcía del Muro Solans, Xavier-
dc.contributor.authorScheffer, G. L.-
dc.contributor.authorScheper, R. J.-
dc.contributor.authorPérez, J.-
dc.contributor.authorGermà Lluch, José Ramón-
dc.contributor.authorIzquierdo, M. A.-
dc.date.accessioned2018-03-13T10:54:50Z-
dc.date.available2018-03-13T10:54:50Z-
dc.date.issued2003-03-24-
dc.identifier.issn0007-0920-
dc.identifier.urihttp://hdl.handle.net/2445/120651-
dc.description.abstractThis study was undertaken to investigate the expression and predictive value for outcome of multidrug resistance-associated (MDR) proteins P-glycoprotein (Pgp), MRP1, BCRP, and LRP, in advanced testicular germ-cell tumours (TGCT). Paraffin-embedded sections from 56 previously untreated patients with metastatic TGCT were immunostained for Pgp, MRP1, BCRP, and LRP. All patients received platinum-based chemotherapy after orchidectomy. Immunostaining was related to clinicopathological parameters, response to chemotherapy, and outcome. Strong and intermediate expressions of the different MDR-related proteins were: 27 and 41% (Pgp), 54 and 37% (MRP1), 86 and 7% (BCRP), and 14 and 29% (LRP). P-glycoprotein and MRP1 associated, respectively, to low AFP (P=0.026) and high LDH levels (P=0.014), whereas LRP expression associated with high β-hCG levels (P=0.003) and stage IV tumours (P=0.029). No correlation was found between Pgp, MRP1, and BCRP expression and response to chemotherapy and survival. In contrast, patients with LRP-positive tumours (strong or intermediate expression) had shorter progression-free (P=0.0006) and overall survival (P=0.0116) than LRP-negative patients, even after individual log-rank adjustments by statistically associated variables. Our data suggest that a positive LRP immunostaining at the time of diagnosis in metastatic TGCT is associated with an adverse clinical outcome.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherCancer Research UK-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/sj.bjc.6600803-
dc.relation.ispartofBritish Journal of Cancer, 2003, vol. 88, num. 6, p. 879-886-
dc.relation.urihttps://doi.org/10.1038/sj.bjc.6600803-
dc.rightscc-by-nc-sa (c) Zurita, A. J. et al., 2003-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationMalalties del testicle-
dc.subject.classificationCèl·lules germinals-
dc.subject.classificationTumors-
dc.subject.classificationExpressió gènica-
dc.subject.classificationProteïnes supressores de tumors-
dc.subject.classificationResistència als medicaments-
dc.subject.otherTestis diseases-
dc.subject.otherGerm cells-
dc.subject.otherTumors-
dc.subject.otherGene expression-
dc.subject.otherTumor suppressor protein-
dc.subject.otherDrug resistance-
dc.titleLung resistance-related protein as a predictor of clinical outcome in advanced testicular germ-cell tumours-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec524876-
dc.date.updated2018-03-13T10:54:50Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid12644825-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
524876.pdf197.12 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons